Focus Stock: Sartorius Continues Recovery After Quarterly Figures

Source: DPA-AFX WIRTSCHAFTSNACHRICHTEN (Glomex)

The strength of Sartorius' Bioprocess Technology division and an optimistic outlook are bringing recovery gains to the laboratory supplier's shares. Historically, however, the shares remain weak. The Sartorius CEO considers the US tariffs manageable.

Leave a Reply